Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma
Issued Date
2022-08-01
Resource Type
eISSN
20457634
Scopus ID
2-s2.0-85126513212
Pubmed ID
35307963
Journal Title
Cancer Medicine
Volume
11
Issue
15
Start Page
2906
End Page
2912
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Medicine Vol.11 No.15 (2022) , 2906-2912
Suggested Citation
Chantharasamee J., Wong K., Potivongsajarn P., Qorbani A., Motamed N., Brackert S., Cohen J., Chmielowski B., Kalbasi A., Rao J., Nelson S., Singh A. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Medicine Vol.11 No.15 (2022) , 2906-2912. 2912. doi:10.1002/cam4.4665 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85697
Title
Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma
Author's Affiliation
Other Contributor(s)
Abstract
Objective: Currently, there is no standard adjuvant treatment protocol for localized uterine leiomyosarcoma (uLMS) as clinical trials to address this question have been retrospective, underpowered, or undermined by slow accrual rates. The aim of this study is to determine the benefit of adjuvant chemotherapy for uLMS. Methods: We reviewed the medical records of localized uLMS patients who had underwent adjuvant therapy after upfront surgery between 2000 and 2020. The cases were blinded for review. We evaluated the influence of various clinical characteristics and different types of adjuvant therapies on specific outcomes. Results: Sixty-eight patients (median age: 50 years) were included for analysis. Forty of 68 (58.8%) patients received adjuvant chemotherapy +/− radiation therapy and 25 patients (38.6%) did not receive any adjuvant therapy. At a median follow-up time of 43.3 months, 45 patients (66.1%) had relapsed disease. The median disease-free survival (mDFS) for all patients was 23.1 months. Patients who received any adjuvant treatment (chemotherapy and/or radiation) trended toward a longer mDFS compared with those who did not receive any adjuvant therapy (29.7 vs. 14.1 months, p = 0.26). Patients who received adjuvant chemotherapy alone had a longer, but nonstatistically significant mDFS compared with those who did not receive any adjuvant treatment (22.2 vs. 14.1 months, p = 0.18). Additionally, univariate analysis found that tumor size large than 10 cm, and a mitotic rate >10/10hpf were independent prognostic factors for worse DFS. Conclusions: Though DFS was more favorable among those who received adjuvant therapy, it was not statistically significant, and thus based on this data adjuvant therapy for resected uLMS is still in question.